RapidArc, intensity modulated photon and proton techniques for recurrent prostate cancer in previously irradiated patients: a treatment planning comparison study

<p<Abstract</p< <p<Background</p< <p<A study was performed comparing volumetric modulated arcs (RA) and intensity modulation (with photons, IMRT, or protons, IMPT) radiation therapy (RT) for patients with recurrent prostate cancer after RT.</p< <p<Methods<...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Ratib Osman [verfasserIn] Khan Haleem G [verfasserIn] Dipasquale Giovanna [verfasserIn] Cozzi Luca [verfasserIn] Wang Hui [verfasserIn] Weber Damien C [verfasserIn] Rouzaud Michel [verfasserIn] Vees Hansjoerg [verfasserIn] Zaidi Habib [verfasserIn] Miralbell Raymond [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2009

Übergeordnetes Werk:	In: Radiation Oncology - BMC, 2006, 4(2009), 1, p 34
Übergeordnetes Werk:	volume:4 ; year:2009 ; number:1, p 34

Links:	Link aufrufen Link aufrufen Link aufrufen Journal toc

DOI / URN:	10.1186/1748-717X-4-34

Katalog-ID:	DOAJ063180448

Internformat


LEADER	01000caa a22002652 4500
001	DOAJ063180448
003	DE-627
005	20230309025308.0
007	cr uuu---uuuuu
008	230228s2009 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.1186/1748-717X-4-34 \|2 doi
035			\|a (DE-627)DOAJ063180448
035			\|a (DE-599)DOAJ7ecd26572d214dacb75499a0c010591c
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
050		0	\|a R895-920
050		0	\|a RC254-282
100	0		\|a Ratib Osman \|e verfasserin \|4 aut
245	1	0	\|a RapidArc, intensity modulated photon and proton techniques for recurrent prostate cancer in previously irradiated patients: a treatment planning comparison study
264		1	\|c 2009
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a <p<Abstract</p< <p<Background</p< <p<A study was performed comparing volumetric modulated arcs (RA) and intensity modulation (with photons, IMRT, or protons, IMPT) radiation therapy (RT) for patients with recurrent prostate cancer after RT.</p< <p<Methods</p< <p<Plans for RA, IMRT and IMPT were optimized for 7 patients. Prescribed dose was 56 Gy in 14 fractions. The recurrent gross tumor volume (GTV) was defined on <sup<18</sup<F-fluorocholine PET/CT scans. Plans aimed to cover at least 95% of the planning target volume with a dose < 50.4 Gy. A maximum dose (D<sub<Max</sub<) of 61.6 Gy was allowed to 5% of the GTV. For the urethra, D<sub<Max </sub<was constrained to 37 Gy. Rectal D<sub<Median </sub<was < 17 Gy. Results were analyzed using Dose-Volume Histogram and conformity index (CI<sub<90</sub<) parameters.</p< <p<Results</p< <p<Tumor coverage (GTV and PTV) was improved with RA (V<sub<95% </sub<92.6 ± 7.9 and 83.7 ± 3.3%), when compared to IMRT (V<sub<95% </sub<88.6 ± 10.8 and 77.2 ± 2.2%). The corresponding values for IMPT were intermediate for the GTV (V<sub<95% </sub<88.9 ± 10.5%) and better for the PTV (V<sub<95%</sub<85.6 ± 5.0%). The percentages of rectal and urethral volumes receiving intermediate doses (35 Gy) were significantly decreased with RA (5.1 ± 3.0 and 38.0 ± 25.3%) and IMPT (3.9 ± 2.7 and 25.1 ± 21.1%), when compared to IMRT (9.8 ± 5.3 and 60.7 ± 41.7%). CI<sub<90 </sub<was 1.3 ± 0.1 for photons and 1.6 ± 0.2 for protons. Integral Dose was 1.1 ± 0.5 Gycm<sup<3 </sup<10<sup<5 </sup<for IMPT and about a factor three higher for all photon's techniques.</p< <p<Conclusion</p< <p<RA and IMPT showed improvements in conformal avoidance relative to fixed beam IMRT for 7 patients with recurrent prostate cancer. IMPT showed further sparing of organs at risk.</p<
653		0	\|a Medical physics. Medical radiology. Nuclear medicine
653		0	\|a Neoplasms. Tumors. Oncology. Including cancer and carcinogens
700	0		\|a Khan Haleem G \|e verfasserin \|4 aut
700	0		\|a Dipasquale Giovanna \|e verfasserin \|4 aut
700	0		\|a Cozzi Luca \|e verfasserin \|4 aut
700	0		\|a Wang Hui \|e verfasserin \|4 aut
700	0		\|a Weber Damien C \|e verfasserin \|4 aut
700	0		\|a Rouzaud Michel \|e verfasserin \|4 aut
700	0		\|a Vees Hansjoerg \|e verfasserin \|4 aut
700	0		\|a Zaidi Habib \|e verfasserin \|4 aut
700	0		\|a Miralbell Raymond \|e verfasserin \|4 aut
773	0	8	\|i In \|t Radiation Oncology \|d BMC, 2006 \|g 4(2009), 1, p 34 \|w (DE-627)508725739 \|w (DE-600)2224965-5 \|x 1748717X \|7 nnns
773	1	8	\|g volume:4 \|g year:2009 \|g number:1, p 34
856	4	0	\|u https://doi.org/10.1186/1748-717X-4-34 \|z kostenfrei
856	4	0	\|u https://doaj.org/article/7ecd26572d214dacb75499a0c010591c \|z kostenfrei
856	4	0	\|u http://www.ro-journal.com/content/4/1/34 \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/1748-717X \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a GBV_ILN_11
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2003
912			\|a GBV_ILN_2005
912			\|a GBV_ILN_2009
912			\|a GBV_ILN_2011
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_2055
912			\|a GBV_ILN_2108
912			\|a GBV_ILN_2111
912			\|a GBV_ILN_2119
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 4 \|j 2009 \|e 1, p 34

Indexfelder

author_variant	r o ro k h g khg d g dg c l cl w h wh w d c wdc r m rm v h vh z h zh m r mr
matchkey_str	article:1748717X:2009----::aiacnestmdltdhtnnpootcnqefreurnpottcneipeiulirdaepte
hierarchy_sort_str	2009
callnumber-subject-code	R
publishDate	2009
allfields	10.1186/1748-717X-4-34 doi (DE-627)DOAJ063180448 (DE-599)DOAJ7ecd26572d214dacb75499a0c010591c DE-627 ger DE-627 rakwb eng R895-920 RC254-282 Ratib Osman verfasserin aut RapidArc, intensity modulated photon and proton techniques for recurrent prostate cancer in previously irradiated patients: a treatment planning comparison study 2009 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier <p<Abstract</p< <p<Background</p< <p<A study was performed comparing volumetric modulated arcs (RA) and intensity modulation (with photons, IMRT, or protons, IMPT) radiation therapy (RT) for patients with recurrent prostate cancer after RT.</p< <p<Methods</p< <p<Plans for RA, IMRT and IMPT were optimized for 7 patients. Prescribed dose was 56 Gy in 14 fractions. The recurrent gross tumor volume (GTV) was defined on <sup<18</sup<F-fluorocholine PET/CT scans. Plans aimed to cover at least 95% of the planning target volume with a dose < 50.4 Gy. A maximum dose (D<sub<Max</sub<) of 61.6 Gy was allowed to 5% of the GTV. For the urethra, D<sub<Max </sub<was constrained to 37 Gy. Rectal D<sub<Median </sub<was < 17 Gy. Results were analyzed using Dose-Volume Histogram and conformity index (CI<sub<90</sub<) parameters.</p< <p<Results</p< <p<Tumor coverage (GTV and PTV) was improved with RA (V<sub<95% </sub<92.6 ± 7.9 and 83.7 ± 3.3%), when compared to IMRT (V<sub<95% </sub<88.6 ± 10.8 and 77.2 ± 2.2%). The corresponding values for IMPT were intermediate for the GTV (V<sub<95% </sub<88.9 ± 10.5%) and better for the PTV (V<sub<95%</sub<85.6 ± 5.0%). The percentages of rectal and urethral volumes receiving intermediate doses (35 Gy) were significantly decreased with RA (5.1 ± 3.0 and 38.0 ± 25.3%) and IMPT (3.9 ± 2.7 and 25.1 ± 21.1%), when compared to IMRT (9.8 ± 5.3 and 60.7 ± 41.7%). CI<sub<90 </sub<was 1.3 ± 0.1 for photons and 1.6 ± 0.2 for protons. Integral Dose was 1.1 ± 0.5 Gycm<sup<3 </sup<10<sup<5 </sup<for IMPT and about a factor three higher for all photon's techniques.</p< <p<Conclusion</p< <p<RA and IMPT showed improvements in conformal avoidance relative to fixed beam IMRT for 7 patients with recurrent prostate cancer. IMPT showed further sparing of organs at risk.</p< Medical physics. Medical radiology. Nuclear medicine Neoplasms. Tumors. Oncology. Including cancer and carcinogens Khan Haleem G verfasserin aut Dipasquale Giovanna verfasserin aut Cozzi Luca verfasserin aut Wang Hui verfasserin aut Weber Damien C verfasserin aut Rouzaud Michel verfasserin aut Vees Hansjoerg verfasserin aut Zaidi Habib verfasserin aut Miralbell Raymond verfasserin aut In Radiation Oncology BMC, 2006 4(2009), 1, p 34 (DE-627)508725739 (DE-600)2224965-5 1748717X nnns volume:4 year:2009 number:1, p 34 https://doi.org/10.1186/1748-717X-4-34 kostenfrei https://doaj.org/article/7ecd26572d214dacb75499a0c010591c kostenfrei http://www.ro-journal.com/content/4/1/34 kostenfrei https://doaj.org/toc/1748-717X Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2108 GBV_ILN_2111 GBV_ILN_2119 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 4 2009 1, p 34
spelling	10.1186/1748-717X-4-34 doi (DE-627)DOAJ063180448 (DE-599)DOAJ7ecd26572d214dacb75499a0c010591c DE-627 ger DE-627 rakwb eng R895-920 RC254-282 Ratib Osman verfasserin aut RapidArc, intensity modulated photon and proton techniques for recurrent prostate cancer in previously irradiated patients: a treatment planning comparison study 2009 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier <p<Abstract</p< <p<Background</p< <p<A study was performed comparing volumetric modulated arcs (RA) and intensity modulation (with photons, IMRT, or protons, IMPT) radiation therapy (RT) for patients with recurrent prostate cancer after RT.</p< <p<Methods</p< <p<Plans for RA, IMRT and IMPT were optimized for 7 patients. Prescribed dose was 56 Gy in 14 fractions. The recurrent gross tumor volume (GTV) was defined on <sup<18</sup<F-fluorocholine PET/CT scans. Plans aimed to cover at least 95% of the planning target volume with a dose < 50.4 Gy. A maximum dose (D<sub<Max</sub<) of 61.6 Gy was allowed to 5% of the GTV. For the urethra, D<sub<Max </sub<was constrained to 37 Gy. Rectal D<sub<Median </sub<was < 17 Gy. Results were analyzed using Dose-Volume Histogram and conformity index (CI<sub<90</sub<) parameters.</p< <p<Results</p< <p<Tumor coverage (GTV and PTV) was improved with RA (V<sub<95% </sub<92.6 ± 7.9 and 83.7 ± 3.3%), when compared to IMRT (V<sub<95% </sub<88.6 ± 10.8 and 77.2 ± 2.2%). The corresponding values for IMPT were intermediate for the GTV (V<sub<95% </sub<88.9 ± 10.5%) and better for the PTV (V<sub<95%</sub<85.6 ± 5.0%). The percentages of rectal and urethral volumes receiving intermediate doses (35 Gy) were significantly decreased with RA (5.1 ± 3.0 and 38.0 ± 25.3%) and IMPT (3.9 ± 2.7 and 25.1 ± 21.1%), when compared to IMRT (9.8 ± 5.3 and 60.7 ± 41.7%). CI<sub<90 </sub<was 1.3 ± 0.1 for photons and 1.6 ± 0.2 for protons. Integral Dose was 1.1 ± 0.5 Gycm<sup<3 </sup<10<sup<5 </sup<for IMPT and about a factor three higher for all photon's techniques.</p< <p<Conclusion</p< <p<RA and IMPT showed improvements in conformal avoidance relative to fixed beam IMRT for 7 patients with recurrent prostate cancer. IMPT showed further sparing of organs at risk.</p< Medical physics. Medical radiology. Nuclear medicine Neoplasms. Tumors. Oncology. Including cancer and carcinogens Khan Haleem G verfasserin aut Dipasquale Giovanna verfasserin aut Cozzi Luca verfasserin aut Wang Hui verfasserin aut Weber Damien C verfasserin aut Rouzaud Michel verfasserin aut Vees Hansjoerg verfasserin aut Zaidi Habib verfasserin aut Miralbell Raymond verfasserin aut In Radiation Oncology BMC, 2006 4(2009), 1, p 34 (DE-627)508725739 (DE-600)2224965-5 1748717X nnns volume:4 year:2009 number:1, p 34 https://doi.org/10.1186/1748-717X-4-34 kostenfrei https://doaj.org/article/7ecd26572d214dacb75499a0c010591c kostenfrei http://www.ro-journal.com/content/4/1/34 kostenfrei https://doaj.org/toc/1748-717X Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2108 GBV_ILN_2111 GBV_ILN_2119 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 4 2009 1, p 34
allfields_unstemmed	10.1186/1748-717X-4-34 doi (DE-627)DOAJ063180448 (DE-599)DOAJ7ecd26572d214dacb75499a0c010591c DE-627 ger DE-627 rakwb eng R895-920 RC254-282 Ratib Osman verfasserin aut RapidArc, intensity modulated photon and proton techniques for recurrent prostate cancer in previously irradiated patients: a treatment planning comparison study 2009 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier <p<Abstract</p< <p<Background</p< <p<A study was performed comparing volumetric modulated arcs (RA) and intensity modulation (with photons, IMRT, or protons, IMPT) radiation therapy (RT) for patients with recurrent prostate cancer after RT.</p< <p<Methods</p< <p<Plans for RA, IMRT and IMPT were optimized for 7 patients. Prescribed dose was 56 Gy in 14 fractions. The recurrent gross tumor volume (GTV) was defined on <sup<18</sup<F-fluorocholine PET/CT scans. Plans aimed to cover at least 95% of the planning target volume with a dose < 50.4 Gy. A maximum dose (D<sub<Max</sub<) of 61.6 Gy was allowed to 5% of the GTV. For the urethra, D<sub<Max </sub<was constrained to 37 Gy. Rectal D<sub<Median </sub<was < 17 Gy. Results were analyzed using Dose-Volume Histogram and conformity index (CI<sub<90</sub<) parameters.</p< <p<Results</p< <p<Tumor coverage (GTV and PTV) was improved with RA (V<sub<95% </sub<92.6 ± 7.9 and 83.7 ± 3.3%), when compared to IMRT (V<sub<95% </sub<88.6 ± 10.8 and 77.2 ± 2.2%). The corresponding values for IMPT were intermediate for the GTV (V<sub<95% </sub<88.9 ± 10.5%) and better for the PTV (V<sub<95%</sub<85.6 ± 5.0%). The percentages of rectal and urethral volumes receiving intermediate doses (35 Gy) were significantly decreased with RA (5.1 ± 3.0 and 38.0 ± 25.3%) and IMPT (3.9 ± 2.7 and 25.1 ± 21.1%), when compared to IMRT (9.8 ± 5.3 and 60.7 ± 41.7%). CI<sub<90 </sub<was 1.3 ± 0.1 for photons and 1.6 ± 0.2 for protons. Integral Dose was 1.1 ± 0.5 Gycm<sup<3 </sup<10<sup<5 </sup<for IMPT and about a factor three higher for all photon's techniques.</p< <p<Conclusion</p< <p<RA and IMPT showed improvements in conformal avoidance relative to fixed beam IMRT for 7 patients with recurrent prostate cancer. IMPT showed further sparing of organs at risk.</p< Medical physics. Medical radiology. Nuclear medicine Neoplasms. Tumors. Oncology. Including cancer and carcinogens Khan Haleem G verfasserin aut Dipasquale Giovanna verfasserin aut Cozzi Luca verfasserin aut Wang Hui verfasserin aut Weber Damien C verfasserin aut Rouzaud Michel verfasserin aut Vees Hansjoerg verfasserin aut Zaidi Habib verfasserin aut Miralbell Raymond verfasserin aut In Radiation Oncology BMC, 2006 4(2009), 1, p 34 (DE-627)508725739 (DE-600)2224965-5 1748717X nnns volume:4 year:2009 number:1, p 34 https://doi.org/10.1186/1748-717X-4-34 kostenfrei https://doaj.org/article/7ecd26572d214dacb75499a0c010591c kostenfrei http://www.ro-journal.com/content/4/1/34 kostenfrei https://doaj.org/toc/1748-717X Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2108 GBV_ILN_2111 GBV_ILN_2119 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 4 2009 1, p 34
allfieldsGer	10.1186/1748-717X-4-34 doi (DE-627)DOAJ063180448 (DE-599)DOAJ7ecd26572d214dacb75499a0c010591c DE-627 ger DE-627 rakwb eng R895-920 RC254-282 Ratib Osman verfasserin aut RapidArc, intensity modulated photon and proton techniques for recurrent prostate cancer in previously irradiated patients: a treatment planning comparison study 2009 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier <p<Abstract</p< <p<Background</p< <p<A study was performed comparing volumetric modulated arcs (RA) and intensity modulation (with photons, IMRT, or protons, IMPT) radiation therapy (RT) for patients with recurrent prostate cancer after RT.</p< <p<Methods</p< <p<Plans for RA, IMRT and IMPT were optimized for 7 patients. Prescribed dose was 56 Gy in 14 fractions. The recurrent gross tumor volume (GTV) was defined on <sup<18</sup<F-fluorocholine PET/CT scans. Plans aimed to cover at least 95% of the planning target volume with a dose < 50.4 Gy. A maximum dose (D<sub<Max</sub<) of 61.6 Gy was allowed to 5% of the GTV. For the urethra, D<sub<Max </sub<was constrained to 37 Gy. Rectal D<sub<Median </sub<was < 17 Gy. Results were analyzed using Dose-Volume Histogram and conformity index (CI<sub<90</sub<) parameters.</p< <p<Results</p< <p<Tumor coverage (GTV and PTV) was improved with RA (V<sub<95% </sub<92.6 ± 7.9 and 83.7 ± 3.3%), when compared to IMRT (V<sub<95% </sub<88.6 ± 10.8 and 77.2 ± 2.2%). The corresponding values for IMPT were intermediate for the GTV (V<sub<95% </sub<88.9 ± 10.5%) and better for the PTV (V<sub<95%</sub<85.6 ± 5.0%). The percentages of rectal and urethral volumes receiving intermediate doses (35 Gy) were significantly decreased with RA (5.1 ± 3.0 and 38.0 ± 25.3%) and IMPT (3.9 ± 2.7 and 25.1 ± 21.1%), when compared to IMRT (9.8 ± 5.3 and 60.7 ± 41.7%). CI<sub<90 </sub<was 1.3 ± 0.1 for photons and 1.6 ± 0.2 for protons. Integral Dose was 1.1 ± 0.5 Gycm<sup<3 </sup<10<sup<5 </sup<for IMPT and about a factor three higher for all photon's techniques.</p< <p<Conclusion</p< <p<RA and IMPT showed improvements in conformal avoidance relative to fixed beam IMRT for 7 patients with recurrent prostate cancer. IMPT showed further sparing of organs at risk.</p< Medical physics. Medical radiology. Nuclear medicine Neoplasms. Tumors. Oncology. Including cancer and carcinogens Khan Haleem G verfasserin aut Dipasquale Giovanna verfasserin aut Cozzi Luca verfasserin aut Wang Hui verfasserin aut Weber Damien C verfasserin aut Rouzaud Michel verfasserin aut Vees Hansjoerg verfasserin aut Zaidi Habib verfasserin aut Miralbell Raymond verfasserin aut In Radiation Oncology BMC, 2006 4(2009), 1, p 34 (DE-627)508725739 (DE-600)2224965-5 1748717X nnns volume:4 year:2009 number:1, p 34 https://doi.org/10.1186/1748-717X-4-34 kostenfrei https://doaj.org/article/7ecd26572d214dacb75499a0c010591c kostenfrei http://www.ro-journal.com/content/4/1/34 kostenfrei https://doaj.org/toc/1748-717X Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2108 GBV_ILN_2111 GBV_ILN_2119 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 4 2009 1, p 34
allfieldsSound	10.1186/1748-717X-4-34 doi (DE-627)DOAJ063180448 (DE-599)DOAJ7ecd26572d214dacb75499a0c010591c DE-627 ger DE-627 rakwb eng R895-920 RC254-282 Ratib Osman verfasserin aut RapidArc, intensity modulated photon and proton techniques for recurrent prostate cancer in previously irradiated patients: a treatment planning comparison study 2009 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier <p<Abstract</p< <p<Background</p< <p<A study was performed comparing volumetric modulated arcs (RA) and intensity modulation (with photons, IMRT, or protons, IMPT) radiation therapy (RT) for patients with recurrent prostate cancer after RT.</p< <p<Methods</p< <p<Plans for RA, IMRT and IMPT were optimized for 7 patients. Prescribed dose was 56 Gy in 14 fractions. The recurrent gross tumor volume (GTV) was defined on <sup<18</sup<F-fluorocholine PET/CT scans. Plans aimed to cover at least 95% of the planning target volume with a dose < 50.4 Gy. A maximum dose (D<sub<Max</sub<) of 61.6 Gy was allowed to 5% of the GTV. For the urethra, D<sub<Max </sub<was constrained to 37 Gy. Rectal D<sub<Median </sub<was < 17 Gy. Results were analyzed using Dose-Volume Histogram and conformity index (CI<sub<90</sub<) parameters.</p< <p<Results</p< <p<Tumor coverage (GTV and PTV) was improved with RA (V<sub<95% </sub<92.6 ± 7.9 and 83.7 ± 3.3%), when compared to IMRT (V<sub<95% </sub<88.6 ± 10.8 and 77.2 ± 2.2%). The corresponding values for IMPT were intermediate for the GTV (V<sub<95% </sub<88.9 ± 10.5%) and better for the PTV (V<sub<95%</sub<85.6 ± 5.0%). The percentages of rectal and urethral volumes receiving intermediate doses (35 Gy) were significantly decreased with RA (5.1 ± 3.0 and 38.0 ± 25.3%) and IMPT (3.9 ± 2.7 and 25.1 ± 21.1%), when compared to IMRT (9.8 ± 5.3 and 60.7 ± 41.7%). CI<sub<90 </sub<was 1.3 ± 0.1 for photons and 1.6 ± 0.2 for protons. Integral Dose was 1.1 ± 0.5 Gycm<sup<3 </sup<10<sup<5 </sup<for IMPT and about a factor three higher for all photon's techniques.</p< <p<Conclusion</p< <p<RA and IMPT showed improvements in conformal avoidance relative to fixed beam IMRT for 7 patients with recurrent prostate cancer. IMPT showed further sparing of organs at risk.</p< Medical physics. Medical radiology. Nuclear medicine Neoplasms. Tumors. Oncology. Including cancer and carcinogens Khan Haleem G verfasserin aut Dipasquale Giovanna verfasserin aut Cozzi Luca verfasserin aut Wang Hui verfasserin aut Weber Damien C verfasserin aut Rouzaud Michel verfasserin aut Vees Hansjoerg verfasserin aut Zaidi Habib verfasserin aut Miralbell Raymond verfasserin aut In Radiation Oncology BMC, 2006 4(2009), 1, p 34 (DE-627)508725739 (DE-600)2224965-5 1748717X nnns volume:4 year:2009 number:1, p 34 https://doi.org/10.1186/1748-717X-4-34 kostenfrei https://doaj.org/article/7ecd26572d214dacb75499a0c010591c kostenfrei http://www.ro-journal.com/content/4/1/34 kostenfrei https://doaj.org/toc/1748-717X Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2108 GBV_ILN_2111 GBV_ILN_2119 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 4 2009 1, p 34
language	English
source	In Radiation Oncology 4(2009), 1, p 34 volume:4 year:2009 number:1, p 34
sourceStr	In Radiation Oncology 4(2009), 1, p 34 volume:4 year:2009 number:1, p 34
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	Medical physics. Medical radiology. Nuclear medicine Neoplasms. Tumors. Oncology. Including cancer and carcinogens
isfreeaccess_bool	true
container_title	Radiation Oncology
authorswithroles_txt_mv	Ratib Osman @@aut@@ Khan Haleem G @@aut@@ Dipasquale Giovanna @@aut@@ Cozzi Luca @@aut@@ Wang Hui @@aut@@ Weber Damien C @@aut@@ Rouzaud Michel @@aut@@ Vees Hansjoerg @@aut@@ Zaidi Habib @@aut@@ Miralbell Raymond @@aut@@
publishDateDaySort_date	2009-01-01T00:00:00Z
hierarchy_top_id	508725739
id	DOAJ063180448
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ063180448</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230309025308.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230228s2009 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1186/1748-717X-4-34</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ063180448</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ7ecd26572d214dacb75499a0c010591c</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">R895-920</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC254-282</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Ratib Osman</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">RapidArc, intensity modulated photon and proton techniques for recurrent prostate cancer in previously irradiated patients: a treatment planning comparison study</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2009</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a"><p<Abstract</p< <p<Background</p< <p<A study was performed comparing volumetric modulated arcs (RA) and intensity modulation (with photons, IMRT, or protons, IMPT) radiation therapy (RT) for patients with recurrent prostate cancer after RT.</p< <p<Methods</p< <p<Plans for RA, IMRT and IMPT were optimized for 7 patients. Prescribed dose was 56 Gy in 14 fractions. The recurrent gross tumor volume (GTV) was defined on <sup<18</sup<F-fluorocholine PET/CT scans. Plans aimed to cover at least 95% of the planning target volume with a dose < 50.4 Gy. A maximum dose (D<sub<Max</sub<) of 61.6 Gy was allowed to 5% of the GTV. For the urethra, D<sub<Max </sub<was constrained to 37 Gy. Rectal D<sub<Median </sub<was < 17 Gy. Results were analyzed using Dose-Volume Histogram and conformity index (CI<sub<90</sub<) parameters.</p< <p<Results</p< <p<Tumor coverage (GTV and PTV) was improved with RA (V<sub<95% </sub<92.6 ± 7.9 and 83.7 ± 3.3%), when compared to IMRT (V<sub<95% </sub<88.6 ± 10.8 and 77.2 ± 2.2%). The corresponding values for IMPT were intermediate for the GTV (V<sub<95% </sub<88.9 ± 10.5%) and better for the PTV (V<sub<95%</sub<85.6 ± 5.0%). The percentages of rectal and urethral volumes receiving intermediate doses (35 Gy) were significantly decreased with RA (5.1 ± 3.0 and 38.0 ± 25.3%) and IMPT (3.9 ± 2.7 and 25.1 ± 21.1%), when compared to IMRT (9.8 ± 5.3 and 60.7 ± 41.7%). CI<sub<90 </sub<was 1.3 ± 0.1 for photons and 1.6 ± 0.2 for protons. Integral Dose was 1.1 ± 0.5 Gycm<sup<3 </sup<10<sup<5 </sup<for IMPT and about a factor three higher for all photon's techniques.</p< <p<Conclusion</p< <p<RA and IMPT showed improvements in conformal avoidance relative to fixed beam IMRT for 7 patients with recurrent prostate cancer. IMPT showed further sparing of organs at risk.</p<</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medical physics. Medical radiology. Nuclear medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Neoplasms. Tumors. Oncology. Including cancer and carcinogens</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Khan Haleem G</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Dipasquale Giovanna</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Cozzi Luca</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Wang Hui</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Weber Damien C</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Rouzaud Michel</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Vees Hansjoerg</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Zaidi Habib</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Miralbell Raymond</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Radiation Oncology</subfield><subfield code="d">BMC, 2006</subfield><subfield code="g">4(2009), 1, p 34</subfield><subfield code="w">(DE-627)508725739</subfield><subfield code="w">(DE-600)2224965-5</subfield><subfield code="x">1748717X</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:4</subfield><subfield code="g">year:2009</subfield><subfield code="g">number:1, p 34</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1186/1748-717X-4-34</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/7ecd26572d214dacb75499a0c010591c</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.ro-journal.com/content/4/1/34</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1748-717X</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2108</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2119</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">4</subfield><subfield code="j">2009</subfield><subfield code="e">1, p 34</subfield></datafield></record></collection>
callnumber-first	R - Medicine
author	Ratib Osman
spellingShingle	Ratib Osman misc R895-920 misc RC254-282 misc Medical physics. Medical radiology. Nuclear medicine misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens RapidArc, intensity modulated photon and proton techniques for recurrent prostate cancer in previously irradiated patients: a treatment planning comparison study
authorStr	Ratib Osman
ppnlink_with_tag_str_mv	@@773@@(DE-627)508725739
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut aut aut aut aut aut aut aut
collection	DOAJ
remote_str	true
callnumber-label	R895-920
illustrated	Not Illustrated
issn	1748717X
topic_title	R895-920 RC254-282 RapidArc, intensity modulated photon and proton techniques for recurrent prostate cancer in previously irradiated patients: a treatment planning comparison study
topic	misc R895-920 misc RC254-282 misc Medical physics. Medical radiology. Nuclear medicine misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens
topic_unstemmed	misc R895-920 misc RC254-282 misc Medical physics. Medical radiology. Nuclear medicine misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens
topic_browse	misc R895-920 misc RC254-282 misc Medical physics. Medical radiology. Nuclear medicine misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Radiation Oncology
hierarchy_parent_id	508725739
hierarchy_top_title	Radiation Oncology
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)508725739 (DE-600)2224965-5
title	RapidArc, intensity modulated photon and proton techniques for recurrent prostate cancer in previously irradiated patients: a treatment planning comparison study
ctrlnum	(DE-627)DOAJ063180448 (DE-599)DOAJ7ecd26572d214dacb75499a0c010591c
title_full	RapidArc, intensity modulated photon and proton techniques for recurrent prostate cancer in previously irradiated patients: a treatment planning comparison study
author_sort	Ratib Osman
journal	Radiation Oncology
journalStr	Radiation Oncology
callnumber-first-code	R
lang_code	eng
isOA_bool	true
recordtype	marc
publishDateSort	2009
contenttype_str_mv	txt
author_browse	Ratib Osman Khan Haleem G Dipasquale Giovanna Cozzi Luca Wang Hui Weber Damien C Rouzaud Michel Vees Hansjoerg Zaidi Habib Miralbell Raymond
container_volume	4
class	R895-920 RC254-282
format_se	Elektronische Aufsätze
author-letter	Ratib Osman
doi_str_mv	10.1186/1748-717X-4-34
author2-role	verfasserin
title_sort	rapidarc, intensity modulated photon and proton techniques for recurrent prostate cancer in previously irradiated patients: a treatment planning comparison study
callnumber	R895-920
title_auth	RapidArc, intensity modulated photon and proton techniques for recurrent prostate cancer in previously irradiated patients: a treatment planning comparison study
abstract	<p<Abstract</p< <p<Background</p< <p<A study was performed comparing volumetric modulated arcs (RA) and intensity modulation (with photons, IMRT, or protons, IMPT) radiation therapy (RT) for patients with recurrent prostate cancer after RT.</p< <p<Methods</p< <p<Plans for RA, IMRT and IMPT were optimized for 7 patients. Prescribed dose was 56 Gy in 14 fractions. The recurrent gross tumor volume (GTV) was defined on <sup<18</sup<F-fluorocholine PET/CT scans. Plans aimed to cover at least 95% of the planning target volume with a dose < 50.4 Gy. A maximum dose (D<sub<Max</sub<) of 61.6 Gy was allowed to 5% of the GTV. For the urethra, D<sub<Max </sub<was constrained to 37 Gy. Rectal D<sub<Median </sub<was < 17 Gy. Results were analyzed using Dose-Volume Histogram and conformity index (CI<sub<90</sub<) parameters.</p< <p<Results</p< <p<Tumor coverage (GTV and PTV) was improved with RA (V<sub<95% </sub<92.6 ± 7.9 and 83.7 ± 3.3%), when compared to IMRT (V<sub<95% </sub<88.6 ± 10.8 and 77.2 ± 2.2%). The corresponding values for IMPT were intermediate for the GTV (V<sub<95% </sub<88.9 ± 10.5%) and better for the PTV (V<sub<95%</sub<85.6 ± 5.0%). The percentages of rectal and urethral volumes receiving intermediate doses (35 Gy) were significantly decreased with RA (5.1 ± 3.0 and 38.0 ± 25.3%) and IMPT (3.9 ± 2.7 and 25.1 ± 21.1%), when compared to IMRT (9.8 ± 5.3 and 60.7 ± 41.7%). CI<sub<90 </sub<was 1.3 ± 0.1 for photons and 1.6 ± 0.2 for protons. Integral Dose was 1.1 ± 0.5 Gycm<sup<3 </sup<10<sup<5 </sup<for IMPT and about a factor three higher for all photon's techniques.</p< <p<Conclusion</p< <p<RA and IMPT showed improvements in conformal avoidance relative to fixed beam IMRT for 7 patients with recurrent prostate cancer. IMPT showed further sparing of organs at risk.</p<
abstractGer	<p<Abstract</p< <p<Background</p< <p<A study was performed comparing volumetric modulated arcs (RA) and intensity modulation (with photons, IMRT, or protons, IMPT) radiation therapy (RT) for patients with recurrent prostate cancer after RT.</p< <p<Methods</p< <p<Plans for RA, IMRT and IMPT were optimized for 7 patients. Prescribed dose was 56 Gy in 14 fractions. The recurrent gross tumor volume (GTV) was defined on <sup<18</sup<F-fluorocholine PET/CT scans. Plans aimed to cover at least 95% of the planning target volume with a dose < 50.4 Gy. A maximum dose (D<sub<Max</sub<) of 61.6 Gy was allowed to 5% of the GTV. For the urethra, D<sub<Max </sub<was constrained to 37 Gy. Rectal D<sub<Median </sub<was < 17 Gy. Results were analyzed using Dose-Volume Histogram and conformity index (CI<sub<90</sub<) parameters.</p< <p<Results</p< <p<Tumor coverage (GTV and PTV) was improved with RA (V<sub<95% </sub<92.6 ± 7.9 and 83.7 ± 3.3%), when compared to IMRT (V<sub<95% </sub<88.6 ± 10.8 and 77.2 ± 2.2%). The corresponding values for IMPT were intermediate for the GTV (V<sub<95% </sub<88.9 ± 10.5%) and better for the PTV (V<sub<95%</sub<85.6 ± 5.0%). The percentages of rectal and urethral volumes receiving intermediate doses (35 Gy) were significantly decreased with RA (5.1 ± 3.0 and 38.0 ± 25.3%) and IMPT (3.9 ± 2.7 and 25.1 ± 21.1%), when compared to IMRT (9.8 ± 5.3 and 60.7 ± 41.7%). CI<sub<90 </sub<was 1.3 ± 0.1 for photons and 1.6 ± 0.2 for protons. Integral Dose was 1.1 ± 0.5 Gycm<sup<3 </sup<10<sup<5 </sup<for IMPT and about a factor three higher for all photon's techniques.</p< <p<Conclusion</p< <p<RA and IMPT showed improvements in conformal avoidance relative to fixed beam IMRT for 7 patients with recurrent prostate cancer. IMPT showed further sparing of organs at risk.</p<
abstract_unstemmed	<p<Abstract</p< <p<Background</p< <p<A study was performed comparing volumetric modulated arcs (RA) and intensity modulation (with photons, IMRT, or protons, IMPT) radiation therapy (RT) for patients with recurrent prostate cancer after RT.</p< <p<Methods</p< <p<Plans for RA, IMRT and IMPT were optimized for 7 patients. Prescribed dose was 56 Gy in 14 fractions. The recurrent gross tumor volume (GTV) was defined on <sup<18</sup<F-fluorocholine PET/CT scans. Plans aimed to cover at least 95% of the planning target volume with a dose < 50.4 Gy. A maximum dose (D<sub<Max</sub<) of 61.6 Gy was allowed to 5% of the GTV. For the urethra, D<sub<Max </sub<was constrained to 37 Gy. Rectal D<sub<Median </sub<was < 17 Gy. Results were analyzed using Dose-Volume Histogram and conformity index (CI<sub<90</sub<) parameters.</p< <p<Results</p< <p<Tumor coverage (GTV and PTV) was improved with RA (V<sub<95% </sub<92.6 ± 7.9 and 83.7 ± 3.3%), when compared to IMRT (V<sub<95% </sub<88.6 ± 10.8 and 77.2 ± 2.2%). The corresponding values for IMPT were intermediate for the GTV (V<sub<95% </sub<88.9 ± 10.5%) and better for the PTV (V<sub<95%</sub<85.6 ± 5.0%). The percentages of rectal and urethral volumes receiving intermediate doses (35 Gy) were significantly decreased with RA (5.1 ± 3.0 and 38.0 ± 25.3%) and IMPT (3.9 ± 2.7 and 25.1 ± 21.1%), when compared to IMRT (9.8 ± 5.3 and 60.7 ± 41.7%). CI<sub<90 </sub<was 1.3 ± 0.1 for photons and 1.6 ± 0.2 for protons. Integral Dose was 1.1 ± 0.5 Gycm<sup<3 </sup<10<sup<5 </sup<for IMPT and about a factor three higher for all photon's techniques.</p< <p<Conclusion</p< <p<RA and IMPT showed improvements in conformal avoidance relative to fixed beam IMRT for 7 patients with recurrent prostate cancer. IMPT showed further sparing of organs at risk.</p<
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2108 GBV_ILN_2111 GBV_ILN_2119 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
container_issue	1, p 34
title_short	RapidArc, intensity modulated photon and proton techniques for recurrent prostate cancer in previously irradiated patients: a treatment planning comparison study
url	https://doi.org/10.1186/1748-717X-4-34 https://doaj.org/article/7ecd26572d214dacb75499a0c010591c http://www.ro-journal.com/content/4/1/34 https://doaj.org/toc/1748-717X
remote_bool	true
author2	Khan Haleem G Dipasquale Giovanna Cozzi Luca Wang Hui Weber Damien C Rouzaud Michel Vees Hansjoerg Zaidi Habib Miralbell Raymond
author2Str	Khan Haleem G Dipasquale Giovanna Cozzi Luca Wang Hui Weber Damien C Rouzaud Michel Vees Hansjoerg Zaidi Habib Miralbell Raymond
ppnlink	508725739
callnumber-subject	R - General Medicine
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
doi_str	10.1186/1748-717X-4-34
callnumber-a	R895-920
up_date	2024-07-03T16:17:27.931Z
_version_	1803575306940841984
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ063180448</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230309025308.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230228s2009 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1186/1748-717X-4-34</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ063180448</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ7ecd26572d214dacb75499a0c010591c</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">R895-920</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC254-282</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Ratib Osman</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">RapidArc, intensity modulated photon and proton techniques for recurrent prostate cancer in previously irradiated patients: a treatment planning comparison study</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2009</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a"><p<Abstract</p< <p<Background</p< <p<A study was performed comparing volumetric modulated arcs (RA) and intensity modulation (with photons, IMRT, or protons, IMPT) radiation therapy (RT) for patients with recurrent prostate cancer after RT.</p< <p<Methods</p< <p<Plans for RA, IMRT and IMPT were optimized for 7 patients. Prescribed dose was 56 Gy in 14 fractions. The recurrent gross tumor volume (GTV) was defined on <sup<18</sup<F-fluorocholine PET/CT scans. Plans aimed to cover at least 95% of the planning target volume with a dose < 50.4 Gy. A maximum dose (D<sub<Max</sub<) of 61.6 Gy was allowed to 5% of the GTV. For the urethra, D<sub<Max </sub<was constrained to 37 Gy. Rectal D<sub<Median </sub<was < 17 Gy. Results were analyzed using Dose-Volume Histogram and conformity index (CI<sub<90</sub<) parameters.</p< <p<Results</p< <p<Tumor coverage (GTV and PTV) was improved with RA (V<sub<95% </sub<92.6 ± 7.9 and 83.7 ± 3.3%), when compared to IMRT (V<sub<95% </sub<88.6 ± 10.8 and 77.2 ± 2.2%). The corresponding values for IMPT were intermediate for the GTV (V<sub<95% </sub<88.9 ± 10.5%) and better for the PTV (V<sub<95%</sub<85.6 ± 5.0%). The percentages of rectal and urethral volumes receiving intermediate doses (35 Gy) were significantly decreased with RA (5.1 ± 3.0 and 38.0 ± 25.3%) and IMPT (3.9 ± 2.7 and 25.1 ± 21.1%), when compared to IMRT (9.8 ± 5.3 and 60.7 ± 41.7%). CI<sub<90 </sub<was 1.3 ± 0.1 for photons and 1.6 ± 0.2 for protons. Integral Dose was 1.1 ± 0.5 Gycm<sup<3 </sup<10<sup<5 </sup<for IMPT and about a factor three higher for all photon's techniques.</p< <p<Conclusion</p< <p<RA and IMPT showed improvements in conformal avoidance relative to fixed beam IMRT for 7 patients with recurrent prostate cancer. IMPT showed further sparing of organs at risk.</p<</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medical physics. Medical radiology. Nuclear medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Neoplasms. Tumors. Oncology. Including cancer and carcinogens</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Khan Haleem G</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Dipasquale Giovanna</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Cozzi Luca</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Wang Hui</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Weber Damien C</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Rouzaud Michel</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Vees Hansjoerg</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Zaidi Habib</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Miralbell Raymond</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Radiation Oncology</subfield><subfield code="d">BMC, 2006</subfield><subfield code="g">4(2009), 1, p 34</subfield><subfield code="w">(DE-627)508725739</subfield><subfield code="w">(DE-600)2224965-5</subfield><subfield code="x">1748717X</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:4</subfield><subfield code="g">year:2009</subfield><subfield code="g">number:1, p 34</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1186/1748-717X-4-34</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/7ecd26572d214dacb75499a0c010591c</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.ro-journal.com/content/4/1/34</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1748-717X</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2108</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2119</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">4</subfield><subfield code="j">2009</subfield><subfield code="e">1, p 34</subfield></datafield></record></collection>
score	7.401025

Nicht das Richtige dabei?

Schreiben Sie uns!

RapidArc, intensity modulated photon and proton techniques for recurrent prostate cancer in previously irradiated patients: a treatment planning comparison study

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?